LONDON (Alliance News) - Intellectual property specialist Frontier IP Group PLC said Thursday it has built a 10% stake in antibiotics company Amprologix Ltd, a spin-out from the University of Plymouth.
Amprologix introduces antibiotics to tackle antimicrobial resistance.
The company will develop and commercialise the work of Mathew Upton, Professor in Medical Microbiology at the university's School of Biomedical Sciences.
Amprologix's first product is expected to be a cream containing epidermicin, one of the new antibiotics being developed to combat infections caused by antibiotic-resistant bacteria.
Amprologix has already secured industry involvement through a partnership with Scottish biotechnology and synthetic biology company Ingenza Ltd.
Chief Executive Officer Neil Crabb said: "We are delighted to work with Amprologix to commercialise these potentially life-saving antibiotics, and with a leading industrial partner in the area. It is further sign our business model is gaining traction with universities and industry alike."
Shares in Frontier IP were up 3.7% Thursday at 56.50 pence each.
Frontier Ip (FIPP)